MIRM — Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Reported total net product revenue of $133 million, a 47% increase year-over-year.
• LIVMARLI Sales: Generated $92 million in net product sales, with $64 million from the U.S. and $28 million internationally.
• Bile Acid Portfolio: Contributed $41 million in net product sales.
• Net Income: Achieved $3 million in net income, marking the first instance of GAAP profitability.
• Cash Position: Cash, cash equivalents, and investments totaled $378 million, reflecting an $85 million increase year-to-date.

2. Strategic Updates and Business Highlights

• Commercial Performance: Strong momentum in the U.S. and international markets, particularly with the PFIC launch and growing demand for LIVMARLI.
• Pipeline Progress: Enrollment completed for the VISTAS Phase IIb study in PSC, with top-line data expected in Q2 2026. Other studies include VANTAGE for PBC and EXPAND for LIVMARLI in cholestatic conditions.
• Product Development: Initiated Phase II study of MRM-3379 for Fragile X syndrome, with promising preclinical data.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Expecting to land at the upper end of the previous guidance range of $500 million to $510 million.
• Growth Potential: Anticipated peak revenue potential for LIVMARLI, volixibat, and MRM-3379 each exceeding $1 billion.

4. Bad News, Challenges, or Points of Concern

• Quarterly Variability: Anticipated flat sequential revenue for Q4 due to variability in international sales and absence of Takeda revenue, which may impact overall performance.
• Competitive Landscape: Concerns regarding competitive pressures in the PBC market, particularly with the recent PDUFA announcement for GSK's linerixibat.
• Adoption of New Formulations: While the solid tablet formulation of LIVMARLI has shown encouraging uptake, ongoing education and engagement are necessary for broader adoption.

5. Notable Q&A Insights

• Drivers of LIVMARLI Performance: Continued focus on expanding the PFIC launch and engaging broader segments of the medical community.
• Pricing Strategy for Volixibat: Pricing analogs are still under consideration, with no final decision made yet.
• Safety Concerns in PSC: No significant safety issues reported in the PSC study, with ongoing monitoring indicating a positive outlook.
• Impact of Government Shutdown: No immediate impact on genetic screening programs or business operations reported due to the government shutdown.
• Business Development Strategy: Mirum remains open to new product opportunities but maintains a high bar for acquisitions, focusing on underappreciated programs.

Overall, Mirum Pharmaceuticals demonstrated strong financial growth and continued progress in its clinical pipeline, while navigating challenges related to market competition and revenue variability.